(NASDAQ: AMGN) Amgen's forecast annual revenue growth rate of 2.18% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.83%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.64%.
Amgen's revenue in 2025 is $34,917,000,000.On average, 12 Wall Street analysts forecast AMGN's revenue for 2025 to be $19,191,364,447,702, with the lowest AMGN revenue forecast at $18,998,789,721,790, and the highest AMGN revenue forecast at $19,317,186,072,623. On average, 12 Wall Street analysts forecast AMGN's revenue for 2026 to be $19,519,553,062,243, with the lowest AMGN revenue forecast at $19,107,231,949,437, and the highest AMGN revenue forecast at $20,027,270,818,322.
In 2027, AMGN is forecast to generate $20,102,409,981,866 in revenue, with the lowest revenue forecast at $19,354,646,905,301 and the highest revenue forecast at $21,235,375,808,078.